Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Phase 3TerminatedNCT06038539

Biocon Biologics UK Ltd55 enrolled

Overview

To compare the efficacy and safety of PERT-IJS (Proposed biosimilar Pertuzumab) plus trastuzumab and chemotherapy (carboplatin and docetaxel) versus EU-Perjeta plus trastuzumab and chemotherapy (carboplatin and docetaxel) in neoadjuvant treatment of patients with HR-ve and HER-2 positive early stage or locally advanced breast cancer.

This study is designed to compare the efficacy and safety of proposed biosimilar PERT-IJS plus trastuzumab, carboplatin and docetaxel versus EU-Perjeta plus trastuzumab, carboplatin and docetaxel in neoadjuvant treatment of HR-ve HER2-positive Early Breast Cancer (EBC) (invasive breast cancer without distant metastasis) or locally advanced breast cancer patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

HR Negative HER2 Positive Early Breast Cancer or Locally Advanced Breast Cancer Patients

Interventions

Perjeta plus trastuzumab, carboplatin and docetaxelBIOLOGICAL

EU Perjeta (Pertuzumab) , an antineoplastic agent, is a recombinant humanized monoclonal antibody that specifically targets sub-domain 2 of the extracellular domain of Human Epidermal Growth Factor Receptor 2 (HER2), blocking heterodimerization of HER2 with other members of the receptor family, including epidermal growth factor, Human Epidermal Growth Factor Receptor 3 (HER3) and Human Epidermal Growth Factor Receptor 4 (HER4).

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patient willing and able to sign informed consent and to follow the protocol requirements 2. Female patients aged ≥ 18 years at the time of Screening 3. Patient with Eastern Cooperative Oncology Group (ECOG) Performance Status \< 2 4. Patients with breast cancer that meets the following criteria: 1. A known case of histologically confirmed invasive breast carcinoma with a primary tumor size of \> 2 cm by standard local assessment technique 2. stage at presentation: early stage (T2-3, N0-1, M0) or locally advanced (T2-3, N2 or N3, M0; T4a-c, any N, M0) or inflammatory (T4d, any N, M0) 5. Patients with HER2 overexpression by Immunohistochemistry (IHC) (defined as IHC 3+, or IHC 2+ with Fluorescence In Situ Hybridization (FISH) confirmation) as per the American Society of Clinical Oncology/College of American Pathologist (ASCO-CAP) guidelines prior to Screening and confirmed centrally before randomization 6. Patients with known HR-ve status (ER-negative and PR-negative) as per local laboratory prior to Screening and confirmed centrally before randomization 7. Patient willing to undergo mastectomy or breast-conserving surgery after neoadjuvant therapy 8. Patient who completes all necessary baseline laboratory and radiologic investigations prior to randomization as per Schedule of assessment (SoA) 9. Patient with baseline left ventricular ejection fraction (LVEF) ≥ 55% measured by echocardiography (ECHO; preferred) or multiple-gated acquisition (MUGA) scan 10. Patient is eligible to participant if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Exclusion Criteria: 1. Patients with metastatic or recurrent bilateral breast cancer, or bilateral breast cancer 2. Patients with a history of concurrent or previously treated non-breast malignancies. A patient with previous invasive non-breast cancer is eligible provided she has been disease free for more than 5 years 3. Patients who have received any previous systemic therapy (including chemotherapy, immunotherapy, HER2-targeted agents, and antitumor vaccines) for treatment or prevention of breast cancer, or radiation therapy for treatment of cancer 4. Concurrent anti-cancer treatment in another investigational study, including hormone therapy or immunotherapy 5. Major surgical procedure that is unrelated to breast cancer within 4 weeks prior to randomization or from which the patient has not fully recovered 6. Serious cardiac illness or medical condition including but not limited to the following as per Investigator's discretion: 1. Patients with ≥ Class II stage of heart failure as per New York Heart Association Classification 2. High risk uncontrolled arrhythmia, such as atrial tachycardia with a heart rate \> 100 bpm at rest, significant ventricular arrhythmia (e.g., ventricular tachycardia) required treatment, or higher-grade atrioventricular (AV) block (i.e., Mobitz II second-degree AV block or third-degree AV block) 3. History of myocardial infarction or unstable angina pectoris within 1 year of randomization or angina pectoris requiring anti-anginal medication 4. Evidence of transmural infarction on ECG 5. Clinically significant valvular heart disease 6. Poorly controlled hypertension (systolic blood pressure \> 180 mmHg and/or diastolic blood pressure \> 100 mmHg) in patients on anti-hypertensive medications 7. Other concurrent serious diseases that may interfere with study primary endpoint and other study assessments, including, but not limited to, severe pulmonary conditions/illness, active liver disease (for example, active viral hepatitis infection \[i.e., hepatitis B or hepatitis C\]), autoimmune disorders, history of or known patient of sclerosing cholangitis, or infection with Human immune deficiency virus (HIV) 8. Patients with a history of any contraindication to the study treatment regimens 9. Any of the following abnormal laboratory test results prior to randomization: 1. Total bilirubin \> upper limit of normal (ULN) or, for cases of known Gilbert's syndrome, total bilirubin \> 2 × ULN 2. Aspartate aminotransferase and/or alanine aminotransferase \> 1.5 × ULN, if considered clinically significant by Investigator 3. Alkaline phosphatase \>2.5 × ULN, if considered clinically significant by Investigator 4. Serum creatinine \> 1.5 × ULN 5. Creatinine clearance \< 60 mL/min 6. Total white blood cells count \< 2500 cells/μL 7. Absolute neutrophil count \< 2000 cells/μL 8. Platelet count \< 100,000 cells/μL 10. Participation in any clinical study with an investigational drug, biologic, or device within 1 month prior or within five half-lives (of the drug/ biologic) prior to the enrolment (whichever is longer) 11. Have taken any live vaccines 30 days prior to the 1st dose of study treatment 12. Any known hypersensitivity to any of the study medications, any of the ingredients or excipients of these medications, or benzyl alcohol 13. Patients unwilling to follow the study requirements. 14. Presence of an uncontrolled, unstable, clinically significant medical condition that, in the opinion of the Investigator, may interfere with the interpretation of efficacy and safety parameters or has a medical condition for which the treatment should take precedence over study participation or will interfere with study participation \-

Outcomes

Primary Outcomes

Efficacy endpoint - Total pathologic complete response between Treatment arm A and Treatment Arm B

Total pathologic complete response (tpCR; ypT0/Tis,ypN0) in breast and axillary nodes after neoadjuvant treatment by Independent Review Committee (IRC)

Time frame: Week 18

Secondary Outcomes

Efficacy endpoint-Total pathologic complete response between Treatment Arm A and Treatment Arm B as neoadjuvant treatment regimen

Total pathologic complete response (tpCR; ypT0/Tis, ypN0) in breast and axillary nodes after neoadjuvant treatment by local histopathologist

Time frame: Week 18

Efficacy endpoint: Pathologic complete response between Treatment Arm A and Treatment Arm B

Pathologic complete response (pCR; ypT0/ypN0) after neoadjuvant treatment by IRC and local histopathologist

Time frame: Week 18

Efficacy endpoint- Breast pathologic complete response between Treatment Arm A and Treatment Arm B as neoadjuvant treatment regimen

Breast pathologic complete response (bpCR; ypT0/Tis) after neoadjuvant treatment by IRC and local histopathologist

Time frame: Week 18

Efficacy endpoint-Objective response rate between Treatment Arm A and Treatment Arm B as neoadjuvant treatment regimen

Objective response rate (ORR) after neoadjuvant treatment in accordance with Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1)

Time frame: Week 18

Efficacy endpoint-Event free survival rate between Treatment Arm A and Treatment Arm B as neoadjuvant treatment regimen

Event free survival (EFS) rate

Time frame: Week 18

Efficacy endpoint- Overall survival rate between Treatment Arm A and Treatment Arm B as neoadjuvant treatment regimen

Overall survival (OS) rate

Time frame: Week 18

Efficacy endpoint-EFS rate of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout

EFS rate

Time frame: 1 Year

Efficacy endpoint - Overall Survival rate of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout

Overall survival rate

Time frame: 1 Year

Efficacy endpoint - Overall Response Rate of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout

Overall Response Rate

Time frame: 1 Year

Efficacy Endpoint: EFS rate after the single switch from EU-Perjeta to PERT-IJS+trastuzumab compared with those continuing on Treatment B

EFS rate after switching of treatment from EU-Perjeta to PERT-IJS + trastuzumab

Time frame: 1 year

Efficacy Endpoint: Disease free survival rate after the single switch from from EU-Perjeta to PERT-IJS+trastuzumab compared with those continuing on EU-Perjeta+trastuzumab

Disease free survival (DFS) rate after switching of treatment from EU-Perjeta to PERT-IJS + trastuzumab versus those continuing on EU-Perjeta + trastuzumab

Time frame: 1 year

Efficacy Endpoint: Overall survival rate after the single switch from from EU-Perjeta to PERT-IJS+trastuzumab compared with those continuing on EU-Perjeta+trastuzumab

OS rate after switching of treatment from EU-Perjeta to PERT-IJS + trastuzumab versus those continuing on EU-Perjeta + trastuzumab

Time frame: 1 year

Pharmacokinetic (PK) endpoint-The trough serum concentration

The trough serum concentration (Ctrough)

Time frame: 1 Year

Safety Endpoint: treatment-emergent adverse events and serious adverse events

Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

Time frame: week 18

Safety Endpoint: left ventricular ejection fraction

Incidence of patients with a decline in left ventricular ejection fraction (LVEF) of ≥ 10% from baseline to \< 50%

Time frame: week 18

Safety Endpoint: Vital signs

Number of subjects with clinically significant changes in Vital signs

Time frame: week 18

Safety Endpoint-ECG PR Interval

Number of subjects with clinically significant changes in ECG PR Interval

Time frame: week 18

Safety Endpoint-ECG QRS Interval

Number of subjects with clinically significant changes in ECG QRS Interval

Time frame: week 18

Safety Endpoint-ECG QT Interval

Number of subjects with clinically significant changes in ECG QT Interval

Time frame: week 18

Safety Endpoint- ECG corrected QT interval (QTc) Interval

Number of subjects with clinically significant changes in ECG QTc Interval

Time frame: week 18

Safety Endpoint-clinical laboratory assessments

Number of subjects with clinically significant changes in Clinical laboratory assessments

Time frame: week 18

Safety Endpoint-pregnancy test

Number of subjects with Pregnancy outcome

Time frame: week 18

Safety Endpoint-physical examination

Number of subjects with clinically significant changes in Physical examination

Time frame: week 18

Immunogenicity Endpoint

Immunogenicity (anti-drug antibodies (ADA) and neutralizing antibodies (nAb) titers)

Time frame: week 18

Safety Endpoint: treatment-emergent adverse events and serious adverse events of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta

Incidence and severity of treatment emergent adverse events (TEAEs) and serious adverse events (SAEs)

Time frame: 1 year

Safety Endpoint: left ventricular ejection fraction of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout

Incidence of patients with a decline in left ventricular ejection fraction (LVEF) of ≥ 10% from baseline to \< 50%

Time frame: 1 year

Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS -throughout compared to patients randomized to EU-Perjeta throughout- Vital signs

Number of subjects with clinically significant changes in Vital signs

Time frame: 1 year

Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout- ECG PR Interval

Number of subjects with clinically significant changes in ECG PR Interval

Time frame: 1 year

Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout-ECG QRS Interval

Number of subjects with clinically significant changes in ECG QRS Interval

Time frame: 1 year

Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout-ECG QT Interval

Number of subjects with clinically significant changes in ECG QT Interval

Time frame: 1 year

Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout- ECG QTc Interval

Number of subjects with clinically significant changes in ECG QTc Interval

Time frame: 1 year

Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout-Clinical laboratory assessments

Number of subjects with clinically significant changes in Clinical laboratory assessments

Time frame: 1 year

Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout- Pregnancy test

Number of subjects with Pregnancy outcome

Time frame: 1 year

Safety Endpoint: Routine safety parameters of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout-Physical examination

Number of subjects with clinically significant changes in Physical examination

Time frame: 1 year

Immunogenicity Endpoint of patients randomized to PERT-IJS throughout compared to patients randomized to EU-Perjeta throughout

Immunogenicity (anti-drug antibodies (ADA) and neutralizing antibodies (nAb) titers)

Time frame: 1 year

Safety Endpoint: Incidence of TEAEs and SAEs after the single switch from EU-Perjeta to PERT-IJS+trastuzumab versus those continuing on EU-Perjeta+trastuzumab throughout

Incidence of TEAEs and SAEs after switching of treatment from EU-Perjeta to PERT-IJS + trastuzumab versus those continuing on EU-Perjeta + trastuzumab

Time frame: 1 Year

Safety End Point :left ventricular ejection fraction incidences after the single switch from EU-Perjeta to PERT-IJS+trastuzumab versus those continuing on EU-Perjeta+trastuzumab

Incidence of patients with a decline in left ventricular ejection fraction (LVEF) of ≥ 10% from baseline to \< 50%

Time frame: 1 year

Immunogenicity End Point: after the single switch from EU-Perjeta to PERT-IJS+trastuzumab versus those continuing on EU-Perjeta+trastuzumab

Immunogenicity (ADA titer and nAb titer) after switching of treatment from EU-Perjeta to PERT-IJS plus trastuzumab versus those continuing on EU-Perjeta + trastuzumab

Time frame: 1 Year

Efficacy and Safety of the Proposed Biosimilar Pertuzumab (PERT-IJS) Versus EU-Perjeta® Along With Trastuzumab and Chemotherapy (Carboplatin and Docetaxel) as Neoadjuvant Treatment in Chemotherapy naïve Patients With Early Stage or Locally Advanced HR Negative and HER2 Positive Breast Cancer

Overview

Conditions

Interventions

Eligibility

Locations (1)

Outcomes

Primary Outcomes

Secondary Outcomes